Acadia

This page shows the latest Acadia news and features for those working in and with pharma, biotech and healthcare.

New leader at Medivir after setbacks

s board in May having previously had a 15-year stint as CEO of Acadia Pharma which came to end in 2015 after the company was forced to delay a filing

Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug

Concludes Acadia Pharmaceuticals’ drug provides ‘modest but meaningful’ benefits. Acadia Pharmaceuticals is celebrating an FDA panel verdict that could set its Nuplazid drug up to be the first approved therapy for ... However, there were some
Clouded vision

AGN 203818 is an orally active, α-adrenoreceptor agonist that was discovered as part of a research programme between Allergan and ACADIA.
Striking a balance

Xsira Pharmaceuticals, 7TM Pharma, Acadia Pharmaceuticals, Glenmark Pharmaceuticals, Esteve, Vernalis, OSI Pharmaceuticals, EPIX Pharmaceuticals, Bayer and Novasite Pharmaceuticals are all undertaking separate research projects to develop CB1
Thomson Scientific publishes quarterly review of phase changes in industry pipeline

Compound. Indication. Company. trazodone. Depression. Labopharm. pimavanserin. Schizophrenia. Acadia Pharmaceuticals. salmon calcitonin.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Jacob Plieth at Vantage recently highlighted this trend, with companies like Tesaro, Clovis Oncology and Acadia failing to meet revenue expectations for their new launches.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Damien McDevitt moves from GSK to Acadia Pharmaceuticals

US biopharmaceutical company Acadia Pharmaceuticals has appointed Damien McDevitt (pictured) as senior vice president of corporate development. ... Meanwhile, Acadia’s SVP, technology development and operations Jim Nash will retire in January.
Juniper Pharmaceuticals adds to board of directors

Dr Gray has over 20 years of biotechnology and biopharmaceutical experience and is the owner and president of Gray Strategic Advisors as well as serving on the boards of Acadia Pharmaceuticals,
Srdjan Stankovic joins Acadia Pharmaceuticals

He moves to the San Diego biopharma from Alkermes. San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development. ... Steve Davis, Acadia's president

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Engagement Expert, Healthcare Brand Communications, London: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Global Business Development Director – Health Education: excellent commission

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Add my company

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....